ResMed Inc. (BVMF:R1MD34)
Brazil · Delayed Price · Currency is BRL | Market Cap | 189.04B -7.0% |
| Revenue (ttm) | 29.29B +9.9% |
| Net Income | 7.89B +8.8% |
| EPS | 13.94 +9.7% |
| Shares Out | n/a |
| PE Ratio | 21.12 |
| Forward PE | 20.67 |
| Dividend | 2.14 (0.73%) |
| Ex-Dividend Date | Aug 19, 2026 |
| Volume | n/a |
| Open | 294.47 |
| Previous Close | 294.47 |
| Day's Range | 294.47 - 294.47 |
| 52-Week Range | 238.41 - 368.49 |
| Beta | 0.75 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Oct 29, 2026 |
About ResMed
ResMed Inc. engages in the digital health and cloud-connected medical devices business in the United States and internationally. It operates in two segments, Sleep and Breathing Health, and Residential Care Software. The company offers sleep recorders for the diagnosis and titration of sleep apnea in sleep clinics, hospitals, and at home, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; NightOwl, a portable, cloud-connected, and disposable diagnostic device that me... [Read more]
Financial Performance
In fiscal year 2026, ResMed's revenue was $5.65 billion, an increase of 9.85% compared to the previous year's $5.15 billion. Earnings were $1.52 billion, an increase of 8.75%.
Financial numbers in USD Financial StatementsNews
Resmed Launches AirTouch™ F40 Full Face Fabric CPAP Mask in the U.S.
SAN DIEGO, Oct. 19, 2026 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD), the leading health technology company focused on sleep, breathing and care delivered in the home, today announced the U.S. la...
ResMed price target raised to $240 from $235 at Mizuho
Mizuho analyst Anthony Petrone raised the firm’s price target on ResMed (RMD) to $240 from $235 and keeps an Outperform rating on the shares. The firm adjusted targets in the…
Resmed to Report First Quarter Fiscal 2027 Earnings on October 29, 2026
SAN DIEGO, Oct. 01, 2026 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD) today announced it plans to release financial and operational results for the first quarter of fiscal year 2027 on Thursday, O...
ResMed Slides: Stewardship presentation
ResMed has posted slides in relation to its latest quarterly earnings report, which was published on September 21, 2026.
Sleep Device Maker ResMed Gets an Upgrade. Analysts See a Lot to Like.
Setbacks for competitors have positioned ResMed to capture more market share.
ResMed Transcript: Morgan Stanley 24th Annual Global Healthcare Conference
Guidance was provided for 5%-7% revenue growth, with strong volume-driven performance and ongoing margin expansion through supply chain productivity. GLP-1s and consumer tech are fueling patient funnel growth, while acquisitions and digital engagement drive adherence. Portfolio management includes new M&A and sunsetting legacy products.
ResMed Slides: Corporate presentation
ResMed has posted slides in relation to its latest quarterly earnings report, which was published on September 15, 2026.
ResMed upgraded to Outperform from Sector Perform at RBC Capital
RBC Capital analyst Craig Wong-Pan upgraded ResMed (RMD) to Outperform from Sector Perform with a price target of $262, up from $244. The company will continue benefiting from increased awareness…
ResMed price target raised to $240 from $235 at Citi
Citi raised the firm’s price target on ResMed (RMD) to $240 from $235 and keeps a Neutral rating on the shares.
ResMed completes divestment of MatrixCare to Frazier Healthcare Partners
Resmed (RMD) announced the closing of its sale of MatrixCare to Frazier Healthcare Partners, a private equity firm focused on the healthcare industry. MatrixCare is a provider of cloud-based electroni...
ResMed Slides: Corporate presentation
ResMed has posted slides in relation to its latest quarterly earnings report, which was published on September 1, 2026.
ResMed price target raised to $267 from $255 at KeyBanc
KeyBanc raised the firm’s price target on ResMed (RMD) to $267 from $255 and keeps an Overweight rating on the shares. The firm walked away from its NDR incrementally comfortable…
Resmed Announces Participation in the 24th Annual Morgan Stanley Global Healthcare Conference
SAN DIEGO, Aug. 27, 2026 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD) today announced Mick Farrell, chairman and chief executive officer, and Aaron Bloomer, chief financial officer, will attend th...
ResMed initiated with a Neutral at Rothschild & Co Redburn
Rothschild & Co Redburn analyst Jackson Philips initiated coverage of ResMed (RMD) with a Neutral rating and $230 price target The firm says Resmed is the “market-leading provider of a…
ResMed management to meet with KeyBanc
Meeting to be held in Montreal on August 26 hosted by KeyBanc.
Resmed Announces Appointment of Carol Burt as Lead Director and Planned Retirement of Director Ron Taylor
SAN DIEGO, Aug. 17, 2026 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD), the leading health technology company focused on sleep, breathing and care delivered in the home, today announced that Carol ...
ResMed shares tumble as weak 2027 sales forecast eclipses quarterly profit beat
Shares of ResMed dropped about 6% in morning trade on Friday after the medtech company forecast fiscal 2027 revenue below Wall Street expectations, impacted by suspended ventilator sales and cost pre...
ResMed price target raised to $244 from $234 at RBC Capital
RBC Capital raised the firm’s price target on ResMed (RMD) to $244 from $234 and keeps a Sector Perform rating on the shares.
ResMed price target lowered to $213 from $217 at Baird
Baird lowered the firm’s price target on ResMed (RMD) to $213 from $217 and keeps a Neutral rating on the shares. The firm updated its model following Q2 results. Published…
ResMed price target lowered to $215 from $225 at Wells Fargo
Wells Fargo analyst Nathan Treybeck lowered the firm’s price target on ResMed (RMD) to $215 from $225 and keeps an Equal Weight rating on the shares. The firm notes the…
ResMed price target lowered to $255 from $260 at KeyBanc
KeyBanc lowered the firm’s price target on ResMed (RMD) to $255 from $260 and keeps an Overweight rating on the shares post Q4. The firm cites lower valuation multiple and…
ResMed reports Q4 EPS $2.95, consensus $2.89
Reports Q4 revenue $1.46B, consensus $1.46B. “We closed fiscal year 2026 with strong fourth quarter results, reflecting continued momentum of our global business, sustained demand for our market-leadi...
ResMed increases quarterly dividend 10% to 66c per quarter
16:27 EDT ResMed (RMD) increases quarterly dividend 10% to 66c per quarter
ResMed Earnings Call Transcript: Q4 2026
Q4 and FY 2026 saw strong revenue and EPS growth, with robust free cash flow and increased capital returns. FY 2027 guidance anticipates 5%-7% core revenue growth, margin expansion, and over $1.85 billion in shareholder returns, despite Astral-related headwinds.